jobs.jnj.com/en/jobs/
Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
48
Innovation

What Are Autoantibodies?

Share
Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
48
More than 200 million people worldwide are living with an autoantibody disease, which occurs when the body attacks its own cells, tissues and proteins.
Today's Top Reads Close

Antibodies are proteins that guard against substances—such as bacteria, fungi, viruses and toxins—that enter your body like foreign invaders. Antibodies protect you by attaching to those invaders (also known as antigens) and triggering your body's natural immune response to destroy them.

You can think of autoantibodies as misguided, or pathogenic, antibodies. Instead of reacting to the antigen, they respond to your body’s own proteins, leading—in some cases—to an abnormal immune response that attacks the cells, tissues and organs of your body and contributes to the development of autoantibody diseases.

"Autoantibody diseases comprise a large and varied group of more than 80 chronic conditions," says Katie Abouzahr, Vice President, Autoantibody Portfolio Development Leader, Janssen Research and Development. They include hemolytic disease of the fetus and newborn, in which a mother's immune system attacks her unborn child's blood cells; warm autoimmune hemolytic anemia, which involves the premature destruction of healthy red blood cells; and myasthenia gravis, a disorder that's characterized by fluctuating weakness in the skeletal muscles.

Autoantibodies can be markers of autoimmune diseases like rheumatoid arthritis or lupus. In fact, more than 2.5% of the population is affected by an autoantibody-driven autoimmune disease.

"Autoantibody diseases represent a significant area of unmet patient need," says Abouzahr. "There are 240 million people worldwide, approximately 3% of the population, who suffer from autoantibody diseases, many without safe and effective treatment options."

That's why Johnson & Johnson is working on immunological advances to help address the need.

Did you like reading this story? Click the heart to show your love.
Empty Heart Icon
48
Learn more about two clinical research studies and eligibility requirements.

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue